Cargando…

Clinical and Immunological Phenotype of Patients With Primary Immunodeficiency Due to Damaging Mutations in NFKB2

Non-canonical NF-κB-pathway signaling is integral in immunoregulation. Heterozygous mutations in NFKB2 have recently been established as a molecular cause of common variable immunodeficiency (CVID) and DAVID-syndrome, a rare condition combining deficiency of anterior pituitary hormone with CVID. Her...

Descripción completa

Detalles Bibliográficos
Autores principales: Klemann, Christian, Camacho-Ordonez, Nadezhda, Yang, Linlin, Eskandarian, Zoya, Rojas-Restrepo, Jessica L., Frede, Natalie, Bulashevska, Alla, Heeg, Maximilian, Al-Ddafari, Moudjahed Saleh, Premm, Julian, Seidl, Maximilian, Ammann, Sandra, Sherkat, Roya, Radhakrishnan, Nita, Warnatz, Klaus, Unger, Susanne, Kobbe, Robin, Hüfner, Anja, Leahy, T. Ronan, Ip, Winnie, Burns, Siobhan O., Fliegauf, Manfred, Grimbacher, Bodo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6435015/
https://www.ncbi.nlm.nih.gov/pubmed/30941118
http://dx.doi.org/10.3389/fimmu.2019.00297
_version_ 1783406582944497664
author Klemann, Christian
Camacho-Ordonez, Nadezhda
Yang, Linlin
Eskandarian, Zoya
Rojas-Restrepo, Jessica L.
Frede, Natalie
Bulashevska, Alla
Heeg, Maximilian
Al-Ddafari, Moudjahed Saleh
Premm, Julian
Seidl, Maximilian
Ammann, Sandra
Sherkat, Roya
Radhakrishnan, Nita
Warnatz, Klaus
Unger, Susanne
Kobbe, Robin
Hüfner, Anja
Leahy, T. Ronan
Ip, Winnie
Burns, Siobhan O.
Fliegauf, Manfred
Grimbacher, Bodo
author_facet Klemann, Christian
Camacho-Ordonez, Nadezhda
Yang, Linlin
Eskandarian, Zoya
Rojas-Restrepo, Jessica L.
Frede, Natalie
Bulashevska, Alla
Heeg, Maximilian
Al-Ddafari, Moudjahed Saleh
Premm, Julian
Seidl, Maximilian
Ammann, Sandra
Sherkat, Roya
Radhakrishnan, Nita
Warnatz, Klaus
Unger, Susanne
Kobbe, Robin
Hüfner, Anja
Leahy, T. Ronan
Ip, Winnie
Burns, Siobhan O.
Fliegauf, Manfred
Grimbacher, Bodo
author_sort Klemann, Christian
collection PubMed
description Non-canonical NF-κB-pathway signaling is integral in immunoregulation. Heterozygous mutations in NFKB2 have recently been established as a molecular cause of common variable immunodeficiency (CVID) and DAVID-syndrome, a rare condition combining deficiency of anterior pituitary hormone with CVID. Here, we investigate 15 previously unreported patients with primary immunodeficiency (PID) from eleven unrelated families with heterozygous NFKB2-mutations including eight patients with the common p.Arg853(*) nonsense mutation and five patients harboring unique novel C-terminal truncating mutations. In addition, we describe the clinical phenotype of two patients with proximal truncating mutations. Cohort analysis extended to all 35 previously published NFKB2-cases revealed occurrence of early-onset PID in 46/50 patients (mean age of onset 5.9 years, median 4.0 years). ACTH-deficiency occurred in 44%. Three mutation carriers have deceased, four developed malignancies. Only two mutation carriers were clinically asymptomatic. In contrast to typical CVID, most patients suffered from early-onset and severe disease manifestations, including clinical signs of T cell dysfunction e.g., chronic-viral or opportunistic infections. In addition, 80% of patients suffered from (predominately T cell mediated) autoimmune (AI) phenomena (alopecia > various lymphocytic organ-infiltration > diarrhea > arthritis > AI-cytopenia). Unlike in other forms of CVID, auto-antibodies or lymphoproliferation were not common hallmarks of disease. Immunophenotyping showed largely normal or even increased quantities of naïve and memory CD4(+) or CD8(+) T-cells and normal T-cell proliferation. NK-cell number and function were also normal. In contrast, impaired B-cell differentiation and hypogammaglobinemia were consistent features of NFKB2-associated disease. In addition, an array of lymphocyte subpopulations, such as regulatory T cell, Th17-, cTFH-, NKT-, and MAIT-cell numbers were decreased. We conclude that heterozygous damaging mutations in NFKB2 represent a distinct PID entity exceeding the usual clinical spectrum of CVID. Impairment of the non-canonical NF-κB pathways affects function and differentiation of numerous lymphocyte-subpopulations and thus causes a heterogeneous, more severe form of PID phenotype with early-onset. Further characteristic features are multifaceted, primarily T cell-mediated autoimmunity, such as alopecia, lymphocytic organ infiltration, and in addition frequently ACTH-deficiency.
format Online
Article
Text
id pubmed-6435015
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-64350152019-04-02 Clinical and Immunological Phenotype of Patients With Primary Immunodeficiency Due to Damaging Mutations in NFKB2 Klemann, Christian Camacho-Ordonez, Nadezhda Yang, Linlin Eskandarian, Zoya Rojas-Restrepo, Jessica L. Frede, Natalie Bulashevska, Alla Heeg, Maximilian Al-Ddafari, Moudjahed Saleh Premm, Julian Seidl, Maximilian Ammann, Sandra Sherkat, Roya Radhakrishnan, Nita Warnatz, Klaus Unger, Susanne Kobbe, Robin Hüfner, Anja Leahy, T. Ronan Ip, Winnie Burns, Siobhan O. Fliegauf, Manfred Grimbacher, Bodo Front Immunol Immunology Non-canonical NF-κB-pathway signaling is integral in immunoregulation. Heterozygous mutations in NFKB2 have recently been established as a molecular cause of common variable immunodeficiency (CVID) and DAVID-syndrome, a rare condition combining deficiency of anterior pituitary hormone with CVID. Here, we investigate 15 previously unreported patients with primary immunodeficiency (PID) from eleven unrelated families with heterozygous NFKB2-mutations including eight patients with the common p.Arg853(*) nonsense mutation and five patients harboring unique novel C-terminal truncating mutations. In addition, we describe the clinical phenotype of two patients with proximal truncating mutations. Cohort analysis extended to all 35 previously published NFKB2-cases revealed occurrence of early-onset PID in 46/50 patients (mean age of onset 5.9 years, median 4.0 years). ACTH-deficiency occurred in 44%. Three mutation carriers have deceased, four developed malignancies. Only two mutation carriers were clinically asymptomatic. In contrast to typical CVID, most patients suffered from early-onset and severe disease manifestations, including clinical signs of T cell dysfunction e.g., chronic-viral or opportunistic infections. In addition, 80% of patients suffered from (predominately T cell mediated) autoimmune (AI) phenomena (alopecia > various lymphocytic organ-infiltration > diarrhea > arthritis > AI-cytopenia). Unlike in other forms of CVID, auto-antibodies or lymphoproliferation were not common hallmarks of disease. Immunophenotyping showed largely normal or even increased quantities of naïve and memory CD4(+) or CD8(+) T-cells and normal T-cell proliferation. NK-cell number and function were also normal. In contrast, impaired B-cell differentiation and hypogammaglobinemia were consistent features of NFKB2-associated disease. In addition, an array of lymphocyte subpopulations, such as regulatory T cell, Th17-, cTFH-, NKT-, and MAIT-cell numbers were decreased. We conclude that heterozygous damaging mutations in NFKB2 represent a distinct PID entity exceeding the usual clinical spectrum of CVID. Impairment of the non-canonical NF-κB pathways affects function and differentiation of numerous lymphocyte-subpopulations and thus causes a heterogeneous, more severe form of PID phenotype with early-onset. Further characteristic features are multifaceted, primarily T cell-mediated autoimmunity, such as alopecia, lymphocytic organ infiltration, and in addition frequently ACTH-deficiency. Frontiers Media S.A. 2019-03-19 /pmc/articles/PMC6435015/ /pubmed/30941118 http://dx.doi.org/10.3389/fimmu.2019.00297 Text en Copyright © 2019 Klemann, Camacho-Ordonez, Yang, Eskandarian, Rojas-Restrepo, Frede, Bulashevska, Heeg, Al-Ddafari, Premm, Seidl, Ammann, Sherkat, Radhakrishnan, Warnatz, Unger, Kobbe, Hüfner, Leahy, Ip, Burns, Fliegauf and Grimbacher. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Klemann, Christian
Camacho-Ordonez, Nadezhda
Yang, Linlin
Eskandarian, Zoya
Rojas-Restrepo, Jessica L.
Frede, Natalie
Bulashevska, Alla
Heeg, Maximilian
Al-Ddafari, Moudjahed Saleh
Premm, Julian
Seidl, Maximilian
Ammann, Sandra
Sherkat, Roya
Radhakrishnan, Nita
Warnatz, Klaus
Unger, Susanne
Kobbe, Robin
Hüfner, Anja
Leahy, T. Ronan
Ip, Winnie
Burns, Siobhan O.
Fliegauf, Manfred
Grimbacher, Bodo
Clinical and Immunological Phenotype of Patients With Primary Immunodeficiency Due to Damaging Mutations in NFKB2
title Clinical and Immunological Phenotype of Patients With Primary Immunodeficiency Due to Damaging Mutations in NFKB2
title_full Clinical and Immunological Phenotype of Patients With Primary Immunodeficiency Due to Damaging Mutations in NFKB2
title_fullStr Clinical and Immunological Phenotype of Patients With Primary Immunodeficiency Due to Damaging Mutations in NFKB2
title_full_unstemmed Clinical and Immunological Phenotype of Patients With Primary Immunodeficiency Due to Damaging Mutations in NFKB2
title_short Clinical and Immunological Phenotype of Patients With Primary Immunodeficiency Due to Damaging Mutations in NFKB2
title_sort clinical and immunological phenotype of patients with primary immunodeficiency due to damaging mutations in nfkb2
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6435015/
https://www.ncbi.nlm.nih.gov/pubmed/30941118
http://dx.doi.org/10.3389/fimmu.2019.00297
work_keys_str_mv AT klemannchristian clinicalandimmunologicalphenotypeofpatientswithprimaryimmunodeficiencyduetodamagingmutationsinnfkb2
AT camachoordoneznadezhda clinicalandimmunologicalphenotypeofpatientswithprimaryimmunodeficiencyduetodamagingmutationsinnfkb2
AT yanglinlin clinicalandimmunologicalphenotypeofpatientswithprimaryimmunodeficiencyduetodamagingmutationsinnfkb2
AT eskandarianzoya clinicalandimmunologicalphenotypeofpatientswithprimaryimmunodeficiencyduetodamagingmutationsinnfkb2
AT rojasrestrepojessical clinicalandimmunologicalphenotypeofpatientswithprimaryimmunodeficiencyduetodamagingmutationsinnfkb2
AT fredenatalie clinicalandimmunologicalphenotypeofpatientswithprimaryimmunodeficiencyduetodamagingmutationsinnfkb2
AT bulashevskaalla clinicalandimmunologicalphenotypeofpatientswithprimaryimmunodeficiencyduetodamagingmutationsinnfkb2
AT heegmaximilian clinicalandimmunologicalphenotypeofpatientswithprimaryimmunodeficiencyduetodamagingmutationsinnfkb2
AT alddafarimoudjahedsaleh clinicalandimmunologicalphenotypeofpatientswithprimaryimmunodeficiencyduetodamagingmutationsinnfkb2
AT premmjulian clinicalandimmunologicalphenotypeofpatientswithprimaryimmunodeficiencyduetodamagingmutationsinnfkb2
AT seidlmaximilian clinicalandimmunologicalphenotypeofpatientswithprimaryimmunodeficiencyduetodamagingmutationsinnfkb2
AT ammannsandra clinicalandimmunologicalphenotypeofpatientswithprimaryimmunodeficiencyduetodamagingmutationsinnfkb2
AT sherkatroya clinicalandimmunologicalphenotypeofpatientswithprimaryimmunodeficiencyduetodamagingmutationsinnfkb2
AT radhakrishnannita clinicalandimmunologicalphenotypeofpatientswithprimaryimmunodeficiencyduetodamagingmutationsinnfkb2
AT warnatzklaus clinicalandimmunologicalphenotypeofpatientswithprimaryimmunodeficiencyduetodamagingmutationsinnfkb2
AT ungersusanne clinicalandimmunologicalphenotypeofpatientswithprimaryimmunodeficiencyduetodamagingmutationsinnfkb2
AT kobberobin clinicalandimmunologicalphenotypeofpatientswithprimaryimmunodeficiencyduetodamagingmutationsinnfkb2
AT hufneranja clinicalandimmunologicalphenotypeofpatientswithprimaryimmunodeficiencyduetodamagingmutationsinnfkb2
AT leahytronan clinicalandimmunologicalphenotypeofpatientswithprimaryimmunodeficiencyduetodamagingmutationsinnfkb2
AT ipwinnie clinicalandimmunologicalphenotypeofpatientswithprimaryimmunodeficiencyduetodamagingmutationsinnfkb2
AT burnssiobhano clinicalandimmunologicalphenotypeofpatientswithprimaryimmunodeficiencyduetodamagingmutationsinnfkb2
AT fliegaufmanfred clinicalandimmunologicalphenotypeofpatientswithprimaryimmunodeficiencyduetodamagingmutationsinnfkb2
AT grimbacherbodo clinicalandimmunologicalphenotypeofpatientswithprimaryimmunodeficiencyduetodamagingmutationsinnfkb2